Risk Assessment of Delayed Cell Engraftment After Cell Therapy

Abstract

Delayed cell engraftment (DCE) following cell therapy presents a significant clinical challenge, impacting treatment outcomes and patient morbidity. This review critically examines the epidemiology, pathophysiological mechanisms, risk factors, clinical features, diagnostic criteria, and management strategies for DCE, while integrating recent advances and guideline-based recommendations. Emphasis is placed on evidence-based assessment tools, mechanistic insights, and the practical implications of identifying and mitigating risk in hematopoietic stem cell and other cellular therapies.

Introduction

Cell therapy, particularly hematopoietic stem cell transplantation (HSCT), has revolutionized the management of a range of hematological malignancies and non-malignant disorders. However, delayed cell engraftment remains a notable complication, associated with increased risk of infection, graft failure, extended hospitalization, and adverse outcomes. Understanding the multifactorial nature of DCE is crucial for optimizing therapeutic strategies and improving patient prognoses.

Epidemiology / Disease Burden

The incidence of DCE varies depending on the type of cell therapy, conditioning regimen, and patient population. In allogeneic HSCT, rates of neutrophil engraftment delay range from 10% to 30% in high-risk cohorts, whereas autologous settings report lower rates. DCE contributes significantly to morbidity, prolongs hospital stays, increases healthcare costs, and is associated with higher non-relapse mortality. Global registry data highlight its prevalence in older adults, patients with comorbidities, and those receiving alternative donor grafts, underscoring its substantial clinical burden.

Pathophysiology

DCE is a complex, multifactorial process involving impaired homing, proliferation, and differentiation of infused progenitor cells. Underlying mechanisms include suboptimal cell dose, graft-versus-host or host-versus-graft immune responses, stromal microenvironment dysfunction, cytokine dysregulation, and the presence of residual disease or infection. Recent studies implicate the bone marrow niche, endothelial adhesion molecule expression, and inflammatory cytokine milieu as critical determinants of engraftment kinetics. Secondary factors such as iron overload and medication toxicity further modulate engraftment dynamics.

Risk Factors

Identifying patients at risk for DCE is essential for preemptive management. Key risk factors include low total nucleated cell or CD34+ cell dose, older recipient or donor age, HLA disparity, use of umbilical cord blood, reduced-intensity conditioning, prior extensive chemotherapy or radiotherapy, bone marrow fibrosis, and active infections at the time of transplantation. Additionally, the use of certain immunosuppressants, graft manipulations (e.g., T-cell depletion), and pre-existing comorbidities such as diabetes or hepatic dysfunction can further elevate risk.

Clinical Features

DCE manifests primarily as persistent cytopenias beyond expected timeframes post-transplantation: neutropenia (ANC < 0.5 × 10⁹/L), thrombocytopenia, and anemia. Patients are consequently at heightened risk for severe infections, mucosal injury, bleeding complications, and delays in subsequent therapies. Atypical presentations may include mixed chimerism or autologous recovery. Vigilant hematological monitoring is required to distinguish DCE from graft failure or relapse.

Diagnosis

The diagnosis of DCE is established based on failure to achieve neutrophil and/or platelet recovery by standard post-transplant days, typically >28 days for neutrophils and >100 days for platelets. Diagnostic evaluation should encompass complete blood counts, bone marrow aspirate and biopsy to assess cellularity and rule out relapse or fibrosis, chimerism analysis, and infectious workup. Molecular and flow cytometric studies may provide additional insights into hematopoietic activity and residual disease.

Treatment & Management

Management of DCE is multifaceted and includes supportive care (antimicrobials, transfusions, growth factors), optimization of immunosuppression, and, where appropriate, secondary cell infusions or stem cell boosts. Granulocyte colony-stimulating factor (G-CSF) is frequently employed to expedite neutrophil recovery. Correction of reversible factors (e.g., infection, medication toxicity, nutritional deficits) is essential. Early consultation with transplant specialists and consideration of donor lymphocyte infusion or retransplantation may be warranted in refractory cases.

Recent Advances / Emerging Therapies

Recent advances focus on enhancing engraftment kinetics through novel conditioning regimens, ex vivo graft manipulation (e.g., expansion, co-infusion of mesenchymal stromal cells), and targeted cytokine therapies. Agents such as plerixafor, thrombopoietin receptor agonists, and engineered cell products aim to improve homing and proliferation. Preclinical and early-phase clinical trials are exploring gene editing to enhance graft resilience and strategies to modulate the bone marrow niche environment. Personalized risk assessment tools incorporating genetic, cellular, and microenvironmental factors are being validated for clinical use.

Guideline Recommendations

International guidelines from bodies such as the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Transplantation and Cellular Therapy (ASTCT) emphasize early risk stratification, routine monitoring of engraftment kinetics, and prompt intervention in cases of delayed recovery. Recommendations include ensuring adequate cell dose, minimizing immunosuppressive toxicity, aggressive management of infections, and consideration of emerging therapies in high-risk or refractory cases. Multidisciplinary collaboration and adherence to protocolized pathways are advocated to optimize outcomes.

Conclusion

Delayed cell engraftment after cell therapy remains a significant clinical concern, necessitating a comprehensive approach to risk assessment and management. Advances in mechanistic understanding, risk stratification, and therapeutic intervention are progressively improving patient outcomes. Ongoing research into graft engineering, niche modulation, and personalized medicine holds promise for further reducing the burden of DCE in the evolving landscape of cell therapy.